![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Spark Biomedical’s Opioid Withdrawal Treatment Earns FDA OK
Spark Biomedical’s Opioid Withdrawal Treatment Earns FDA OK
![FDA clears text](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA-clears.gif?t=1619732616&width=430)
The FDA has granted 510(k) marketing clearance for Spark Biomedical’s Sparrow Therapy system, a wearable neurostimulator for treating opioid withdrawal.
The system, which is designed to be worn up to 24 hours a day during detoxification, stimulates nerves on and around the ear to help reduce withdrawal symptoms.
The Sparrow system is “the first clinically proven, drug-free, needle-free, wearable neurostimulation solution for opioid withdrawal relief,” offering an alternative to treatments that use drugs or acupuncture, Spark said.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct